Research programme: melanin-concentrating hormone receptor 1 antagonists - Ligand

Drug Profile

Research programme: melanin-concentrating hormone receptor 1 antagonists - Ligand

Alternative Names: MCH programme - Ligand; Melanin-concentrating hormone programme - Ligand

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurogen Corporation
  • Developer Ligand Pharmaceuticals
  • Class
  • Mechanism of Action MCHR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA
  • 06 Jul 2010 Preclinical development is ongoing in USA
  • 11 Jan 2008 Neurogen Corporation is considering partnership and/or out-licensing opportunities for this research programme (http://www.nrgn.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top